Abstract: BACKGROUND: Vascular calcification independently predicts cardiovascular disease, the major cause of death in kidney transplant recipients (KTRs). Longitudinal studies of vascular calcification in KTRs are few and small and have short follow-up. We assessed the evolution of coronary artery (CAC) and thoracic aorta calcification and their determinants in a cohort of prevalent KTRs. STUDY DESIGN: Longitudinal. SETTING PARTICIPANTS: The Agatston score of coronary arteries and thoracic aorta was measured by 16-slice spiral computed tomography in 281 KTRs. PREDICTORS: Demographic, clinical, and biochemical parameters were recorded simultaneously. OUTCOMES MEASUREMENTS: The Agatston score was measured again 3.5 or more years later. RESULTS: Repeated analyzable computed tomographic scans were available for 197 (70%) KTRs after 4.40 ± 0.28 years; they were not available for the rest of patients because of death (n = 40), atrial fibrillation (n = 1), other arrhythmias (n = 4), refusal (n = 35), or technical problems precluding confident calcium scoring (n = 4). CAC and aorta calcification scores increased significantly (by a median of 11% and 4% per year, respectively) during follow-up. By multivariable linear regression, higher baseline CAC score, history of cardiovascular event, use of a statin, and lower 25-hydroxyvitamin D(3) level were independent determinants of CAC progression. Independent determinants of aorta calcification progression were higher baseline aorta calcification score, higher pulse pressure, use of a statin, older age, higher serum phosphate level, use of aspirin, and male sex. Significant regression of CAC or aorta calcification was not observed in this cohort. LIMITATIONS: Cohort of prevalent KTRs with potential survival bias; few patients with diabetes and nonwhites, limiting the generalizability of results. CONCLUSION: In contrast to previous small short-term studies, we show that vascular calcification progression is substantial within 4 years in prevalent KTRs and is associated with several traditional and nontraditional cardiovascular risk factors, some of which are modifiable. 
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of premature death in RTR, with a 3.5 to 5% annual risk of fatal or non-fatal CV events (CVE), much higher than in the general population despite adjustment for traditional risk factors (1, 2) . A high prevalence of vascular calcification has been demonstrated in patients with chronic kidney disease (CKD), with higher calcification scores than in age-and gender-matched non-renal patients with coronary heart disease (3) (4) (5) . Vascular calcification may involve either the intima, in association with inflammation and atherosclerosis, or the media, causing vascular stiffness. Both processes often coexist in advanced CKD and cannot be distinguished by imaging techniques, including computed tomography (CT) (6) . Still, vascular calcification strongly predicts CVD and all-cause mortality not only in hemodialysis and peritoneal dialysis patients (7-9) but also in RTR (10) (11) (12) . Moreover, coronary artery calcification (CAC) progression also predicts CVE and mortality in RTR (12) . Only few small-sized studies relying on CT have assessed CAC progression in RTR (13) (14) (15) (16) .
In the present study a large prevalent RTR cohort underwent CT at inclusion and ~4 years later to assess the evolution of coronary artery and thoracic aorta calcification (AoC). The relationship between clinical, demographic, biological markers and calcification score at baseline and progression of vascular calcification was investigated.
We hypothesized that vascular calcification progresses substantially in stable renal transplant recipients and that independent determinants of both CAC and AoC progression include both classical and non-classical cardiovascular (CV) risk factors.
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PATIENTS AND METHODS
Patients
The prevalent Brussels Renal Transplant Cohort was initiated from February 3rd
2004 to January 27th 2005. All RTR with a functional graft for ≥ 1 year attending the outpatient clinic of the Cliniques universitaires Saint Luc (UCL, Brussels) for their annual or bi-annual in-depth control were asked to enter the study. The protocol was approved by the Ethics Committee of the UCL Medical School and written informed consent was obtained from all patients. Exclusion criteria were age under 18, residing abroad or being recipient of a multi-organ transplant. Three hundred nineteen patients were contacted, 300 of whom entered the study.
Spiral CT scan
At inclusion 281 patients underwent chest multi-slice spiral CT on a 16-slice scanner (Brillance 16, Philips Healthcare, www.healthcare.philips.com). The thoracic aorta and the four branches of the main coronary arteries were individually scored as previously described (17) . Agatston scores of coronary arteries (CAC) and thoracic aorta (AoC) were measured using a manufacturer algorithm (Heart Beat CS, Philips Healthcare, www.healthcare.philips.com) and expressed in mg. Intra-reader variability was 3 % and 8 % respectively for CAC and AoC (17) . The Agatston score was again measured ≥ 3.5 years later. All CT studies were performed at baseline and follow-up on the same machine using the same conditions of CT acquisition and the same scoring software.
6
Clinical and biological parameters
At baseline, demographic, clinical and medical history parameters including history of cardiovascular event (CVE) (defined as myocardial, cerebrovascular or lower limb necrosis or revascularization or documented transient ischemic attack (18) (20) . Glomerular filtration rate was estimated by the abbreviated MDRD formula at time of inclusion. Induction and maintenance immunosuppressive drugs and all drugs prescribed at inclusion were recorded.
Statistical analysis
Results are presented as means ± SD, median [P25-P75] or n (and %) as appropriate. Variables presenting a right skewed distribution were log-transformed.
Univariate analysis was performed using the t-test, Wilcoxon sign-rank test or Chi-square test as applicable.
Multiple stepwise linear regression using annualized absolute rate of change as a continuous variable was performed to identify determinants of CAC or AoC progression.
We computed the annualized absolute rate of change of vascular calcification (CAC or AoC) as the difference of Agatston score between the first and second scan divided by the time between scans. The annualized absolute rates of change were log-transformed.
All variables reaching in univariate analysis the p < 0.2 level entered the multivariable models. To handle the major issue of competing risk for having a follow-up scan versus death, we performed sensitivity analyses with dead patients classified as having progression of CAC or AoC either similar or greater than the cohort. Similar CAC or AoC progression was defined as 14% or 10% (median) progression respectively, over 4.4 years. Greater CAC or AoC progression was defined as 57% or 48% (third tertile) progression respectively, over 4.4 years.
We compared non progressors, slow and high progressors. For this analysis we computed the percentage annualized rate as the absolute rate divided by the initial score (CAC or AoC). The analysis comparing non progressors, slow and high progressors included only patients with a score of 0 or higher than 30 because with low (but different from 0) baseline scores, there is a substantial risk of overestimation of the percentage change of score over time (15, 21) . For patients with CAC or AoC at baseline scored 0 or higher than 30, progressors were divided in three groups (tertiles). Subjects with a CAC or AoC score of 0 and a follow-up score > 4 were considered as high progressors (14) .
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All statistical analyses were performed using SPSS 15.0 software. All tests were two-tailed and a p-value < 0.05 was considered as significant.
RESULTS
Out of the initial 281 patients' cohort, forty patients died before the appointment for the second CT and one had atrial fibrillation precluding a successful scan. Thirty-five declined to undergo a second CT. Two hundred and five patients thus had a repeat CT after 4.40 (± 0.28) years. Calcium scoring could not be performed in 8 patients of them, due to technical problems (n=4) or arrhythmias (n=4). Thus the study cohort included 197 patients ( Figure 1 ). Patients resuming dialysis (n=14) were not censored.
Characteristics of the patients
The 197 patients were 98 % Caucasian, 57 % male, aged 52 ± 12 years, transplanted for 93 ± 78 months (Table 1) . A history of CVE was recorded in 48 patients The cause of end-stage renal disease was chronic glomerulonephritis (n = 66; 34 %), chronic interstitial nephropathy (n = 60; 30 %), polycystic kidney disease (n = 38; 19 %), nephrosclerosis (n = 9; 5 %), diabetic nephropathy (n = 6; 3 %) and others/unknown (n = 
Vascular calcification at baseline and follow-up
At The absolute annualized CAC and AoC progression were highly correlated (p<0.001) ( Figure 4 ). A few individuals had decreases in CAC (n = 5) and/or in AoC (n = 13). In some of them, these changes were (very) small and consistent with the variability of the measure. In some others, careful review of paired scans ascribed apparent regressions to artifacts. Overall, there was no solid evidence of regression of either CAC or AoC in any patient.
Determinants of CAC progression
Among patients with an initial CAC score of 0 or higher than 30 (n = 172), 55 met the definition of high CAC progressors (Table 2) . Age, gender, diabetes and homocysteine, parathyroid hormone and 25-(OH) vitamin D3 levels (but not graft function) were significantly different between non progressors, slow and high CAC progressors.
By univariate regression analysis, older age, male gender, history of CVE, systolic blood pressure, pulse pressure, use of statin, time on dialysis, 25-(OH) vitamin D3 and PTH levels, and CAC baseline score were associated with annualized absolute CAC progression (Table 3 ). In a multivariable regression model, CAC baseline score, history of CVE, use of statin and level of 25-(OH) vitamin D3 were independently associated with the annualized absolute CAC progression (R² = 0.29, p<0.001) ( Table 3) .
Sensitivity analyses performed in 237 patients did not change the determinants of CAC progression. The relationship between a low level of 25(OH)vitD3 and CAC progression was even strengthened in the greater progression analysis (Supplementary tables 1 and 2).
Determinants of AoC progression
Among patients with an AoC score of 0 or higher than 30 (n = 166), 60 met the definition of high AoC progression (Table 4) . Age, history of CVE, use of statin and cyclosporine, and levels of phosphate and 25-(OH) vitamin D3 (but not graft function)
were significantly different between non progressors, slow and high AoC progressors.
By univariate regression analysis, older age, male gender, history of CVE, diabetes, systolic blood pressure, pulse pressure, diabetes or hypertension as cause of ESRD, living donor TP, use of statin and aspirin, fetuin-A and phosphate levels as well as
AoC baseline score were associated with annualized absolute AoC progression (Table 5 ).
In a multivariable regression model AoC baseline score, pulse pressure, use of statin, age, phosphate level, use of aspirin and gender were independently associated with the annualized absolute AoC progression (R² = 0.42, p<0.001) ( Table 5) . Sensitivity analyses performed in 237 patients showed that determinants of AoC progression were largely unchanged in both the similar and greater progression analyses, with only phosphate level no longer reaching significance (p = 0.06) (Supplementary tables 3 and 4).
DISCUSSION
To the best of our knowledge, the current study is the first one to assess the progression of both CAC and AoC in a large population of stable RTR with a relatively long follow-up time. Our major finding is that vascular calcification progresses substantially within 4 years in prevalent RTR: CAC increased by a median of 11 % per year and AoC increased by a median of 4 % per year in RTR with a baseline vascular score higher than 30 (21) . In 25 percent of patients the yearly increase of CAC and AoC 12 reached or exceeded 23 % and 17 % respectively. The independent determinants of both CAC and Aoc progression include both classical and non-classical CV risk factors, some of them modifiable.
Only four series previously assessed the progression of CAC in RTR (13) (14) (15) (16) . All these cohorts were much smaller and intervals between CT scans were shorter. Again, no significant progression of AoC was detected, in contrast to our study, probably as a result of a small cohort and short follow-up time. (Table 5 versus   Supplementary table 5) .
Our second aim was to investigate the determinants of vascular calcification progression in RTR. For CAC, these include a higher baseline CAC score, a history of CVE, the use of a statin and a lower 25-(OH) vitamin D3 level. Restricting the analysis to patients with a baseline score > 0 (n = 149) does not change the results (data not shown).
That a higher baseline CAC score is associated with CAC progression confirms previous studies both in RTR (14) and in hemodialysis patients (13) . Studies in dialysis patients as well as in renal transplant recipients have demonstrated the strong association of CVE history with CAC, the latter most likely related to atherosclerosis (23, 24, 25, 19) calcification by decreasing type 1 collagen production, which plays an important role in calcium deposition (30) . Observational studies already showed that vitamin D deficiency is associated with increased risks for cardiovascular disease and death in the general population (31, 32), with heart failure in patients referred for coronary angiography (33) and with mortality in hemodialysis and CKD patients (34, 35) . Moreover low 25-(OH) vitamin D3 levels are associated with traditional atherosclerosis risk factors (36) (37) (38) (39) .
These studies suggest a potential role for vitamin D therapy in these populations.
Randomized controlled trials are thus required to test the potential benefits of vitamin D treatment on those outcomes. In incident RTR, diastolic blood pressure, GFR, BMI (14) 15 as well as smoking (15) were determinants of CAC progression. In our cohort of prevalent RTR, these parameters were not independent determinants of CAC progression.
The independent determinants of AoC progression are a higher baseline AoC score, a higher pulse pressure, the use of a statin, older age, a higher level of phosphate, the use of aspirin and male gender. Restricting the analysis to patients with a baseline score > 0 (n = 161) did not change the results (data not shown). Older age and male gender are classical CV risk factors (23, 24, 18, 40) . Like for CAC progression, use of statin and baseline score were associated with AoC progression. We also show an association of AoC progression with a higher pulse pressure, independently of baseline
AoC. This association is of interest, as it suggests that a stiffer aorta could be a risk factor for the progression of aortic calcification, independently of the initial extent of the latter.
A high pulse pressure (a surrogate for arterial stiffness) is indeed a well established cardiovascular risk factor (41) and both a cause and a consequence of atherosclerosis.
The endothelium regulates the vascular tone and cardiovascular homeostasis. Endothelial dysfunction reduces nitric oxide (NO) bioavailability and is associated with the onset and progression of atherosclerosis (42) (43) and with arterial calcification resulting in arterial stiffness (44) (45) (46) . This link is further supported by an in vivo study showing that exercise prevented the decrease in eNOS expression and NO production and reduced arterial calcification in ovariectomized rats (47) . Furthermore, other studies have reported an association between high pulse pressure and endothelial dysfunction (48) (49) (50) . It was also observed that NO may regulate arterial distensibility, and thus possibly pulse pressure (51) . On the other hand, the elevation of pulse pressure may also exert a negative feedback on the endothelium (52) . Overall, these results are in line with our findings and 16 suggest that a high pulse pressure may be a risk factor for AoC progression. The use of aspirin at inclusion predicts AoC progression in our study. Like for the statins, this observation is probably related to confounding by indication. We also identified a higher phosphate level as predictor of AoC progression, independently of eGFR. Studies in healthy adults (53) and CKD patients (54) already observed an association of higher phosphatemia with atherosclerosis and vascular calcification. Russo et al. established in a cohort of predialysis patients that higher phosphorus levels were associated with CAC progression (55) . Another study performed in CKD patients observed an association between higher phosphorus levels and mortality (56) . Again, hypotheses generated by observational studies require testing in randomized trials, in order in this case to assess the impact of phosphate binders on survival or AoC progression (57) .
The strengths of our study, the first to examine the progression of both CAC and AoC in a large population of stable RTR, include the sample size, the 4-year follow-up, the use of an identical multi-slice spiral CT at baseline and follow-up. Some limitations should be acknowledged. First, the study population is typical of RTR followed in analyses however showed that our results are robust. Finally, the inclusion of prevalent rather than incident RTR patients may have introduced a survival bias.
In conclusion, the present study shows that vascular calcification progresses substantially in stable renal transplant recipients. The independent determinants of both CAC and Aoc progression include both classical and non-classical CV risk factors, some of them modifiable. Conversion factors for units: serum creatinine in mg/dL to µmol/L, x88.4; glucose in mg/dL to mmol/L, x0.05551; hemoglobin in g/dL to g/L, x10; total cholesterol in mg/dL to mmol/L, x0.02586; HDL cholesterol in mg/dL to mmol/L, x0.02586; 25(OH) vitD3 in ng/mL to nmol/L, x2.496; 1-25(OH) vitD3 in pg/mL to pmol/L, x2.6; calcium in mg/dL to mmol/L, x0.2495; phosphate in mg/dL to mmol/L, x0.3229; magnesium in mEq/L to mmol/L, x0.5; PTH in pg/mL to µmol/L, x11.1. 
Demographics and comorbidity
Age (y) 46 (14) 54 (9) 
